Potential of nanoparticulate drug delivery systems by intranasal administration

Current Pharmaceutical Design

Volumn 16, Issue 14, 2010, Pages 1644-1653

  Ali, Javed ^a   Ali, Mushir ^a   Baboota, Sanjula ^a   Sahni, Jasjeet Kaur ^a   Ramassamy, Charles ^b   Dao, Lé ^c   Bhavna, ^a  

^a HAMDARD UNIVERSITY   (India)

^b INRS INSTITUT ARMAND FRAPPIER   (Canada)

^c INRS EMT   (Canada)

Author keywords

Brain delivery; Intranasal delivery; Nanoparticulate system; Systemic delivery; Topical delivery; Vaccine delivery

Indexed keywords

BUSERELIN; CLONAZEPAM; CYANOCOBALAMIN; DESMOPRESSIN; ESTRADIOL; FENTANYL; INFLUENZA VACCINE; INSTANYL; INSULIN; NAFARELIN ACETATE; NANOCARRIER; NICOTINE; NIMODIPINE; NOSE DROPS; NOSE SPRAY; OXYTOCIN; RISPERIDONE; SALCATONIN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; THEOPHYLLINE; THYROTROPIN; ULEX EUROPAEUS AGGLUTININ; UNCLASSIFIED DRUG; ZOLMITRIPTAN; NANOPARTICLE;

ARTICLE; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BLOOD FLOW; CONTROLLED DRUG RELEASE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SOLUBILITY; ENZYME ACTIVITY; HUMAN; LIPOPHILICITY; LOCAL THERAPY; MICROEMULSION; MOLECULAR WEIGHT; MUCOCILIARY CLEARANCE; NANOEMULSION; OSMOLARITY; PARTICLE SIZE; PH; PRIORITY JOURNAL; SURFACE PROPERTY; VACCINE DELIVERY; ANIMAL; BRAIN; INTRANASAL DRUG ADMINISTRATION; METABOLISM; REVIEW;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES;

EID: 77953916083     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791164108     Document Type: Article

References (98)

1. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of using chitosan nanoparticles. Pharm Res 1999; 16: 1576-81.
2. Betbeder D, Sperandio S, Latapie JP, Nadai J, Etienne A, Zajac JM, et al. Biovector TM nanoparticles improve antinociceptive efficacy of nasal morphine. Pharm Res 2000; 17: 743-8.
3. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Del Rev 2001; 47: 83-97.
4. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release 2002; 78: 15-24.
5. Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res 2004; 21: 671-4.
6. Donovan MD, Huang Y. Large molecule and particulate uptake in the nasal cavity: The effect of size on nasal absorption. Adv Drug Del Rev 1998; 29: 147-55.
7. Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, et al. Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res 2002; 19: 998-1008.
8. Cui Z, Mumper RJ. Intranasal administration of plasmid DNAcoated nanoparticles results in enhanced immune responses. J Pharm Pharmacol 2002; 54: 1195-203.
9. Lemarchand C, Gref R, Couvreur P. Polysachharide-decorated nanoparticles. Eur J Pharm Biopharm 2004; 58: 327-41.
10. Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Jato JLV, et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 2004; 57: 123-31
11. Chein YW, Su KS, Chang SF. Nasal systemic drug delivery. 2nd ed. New York: Dekker 1989; p. 26.
12. Kissel T, Werner U. Nasal delivery of peptides: an in vitro cell culture model for the investigation of transport and metabolism in human nasal epithelium. J Control Release 1998; 53: 195-203.
13. Ridley D, Perkins AC, Washington N, Wilson CG, Wastie ML, Flynn PO. The effect of posture on thre nasal clearance of bioadhesive starch microspheres. STP Pharma Sci 1995; 5: 442-6.
14. Lllumm L, Drug delivery systems for nasal application. In: Hincal AA, Kas HS, Sumnu M, editors Third international Pharmaceutical Technology Symposium [Proccedings]. Ankara: Meteksan 1985.
15. Mygind N. Scanning electron microscopy of the human nasal mucosa. Rhinology 1975; 13: 57-75.
16. Watanabe K, Watanabe I, Saito Y, Mizuhira V. Characteristics of capillary permeability in nasal mucosa. Ann Otol Rhinol Laryngol 1980; 89: 377-82.
17. Geurkink N. Nasal anatomy, physiology, and function. J Allergy Clin Immunol 1983; 72: 123-8.
18. Brofeldt S, Secher C, Mygind N. Biophysical characteristics of nasal secretions: A preliminary report. Eur J Respir Dis 1983; 64: 436-40.
19. Bende M. Studies of blood flow in the human nasal mucosa. Eur J Respir Dis 1983; 64: 400-2.
20. Bisgaard H, Krogsgaard O, Mygind N. Measurement of secretion in nasal lavage. Clin Sci 1987; 73: 217-22.
21. Dawes JD, Prichard M. Studies of the vascular arrangement of the nose. J Anat 1953; 87: 311-22.
22. Cauna N, Hinderer KH. Fine structure of blood vessels of the human nasal respiratory mucosa. Ann Otol Rhinol Laryngol 1969; 78: 865-85.
23. Pomponi M, Giacobini E, Brufani M. Present state and future development of the therapy of Alzheimer's disease. Aging 1990; 2: 125-53.
24. Mygind N, Anggard A. Anatomy and physiology of the nosepathophysiology alterations in allergic rhinitis. Clin Rev Allergy 1984; 2: 173-88.
25. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000; 11: 1-18.
26. Dahl R, Mygind N. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Del Rev 1998; 29: 3-12.
27. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Del Rev 2005; 57: 1640-65.
28. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target 1998; 5: 415-41.
29. Dhanda DS, Frey WH, Leopold D, Kompella U. Nose to brain delivery: approaches for drug deposition in human olfactory epithelium. Drug Deliv Technol 2005; 5: 1-9.
30. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004; 56: 3-17.
31. Schipper NG, Verhoef JC, Merkus FW. The nasal mucocilliary clearance: relevance to nasal drug delivery. Pharm Res 1991; 8: 807-14.
32. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction. J Drug Target 1998; 5: 415-41.
33. Chien YW, Chang SF. Intranasal drug delivery for systemic medication. Crit Rev Ther Drug Carrier Syst 1987; 4: 67-194.
34. Hehar SS, Mason JD, Stephen AB. Twenty four hour ambulatory nasal pH monitoring. Clin Otolaryngol 1999; 24: 24-5.
35. Geurkink N. Nasal anatomy, physiology, and function. J Allergy Clin Immunol 1983; 72: 123-8.
36. Mygind N, Anggard A. Anatomy and physiology of the nosepathophysiology alterations in allergic rhinitis. Clin Rev Allergy 1984; 2: 173-88.
37. Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Parry HG, Tipton IH. Report of the task group on reference man. ed. 1. Oxford: Pergamon Press 1975.
38. Sarkar MA. Drug metabolism in the nasal mucosa. Pharm Res 1992; 9: 1-9.
39. DeSesso JM. The relevance to humans of animal models for inhalation studies of cancer in the nose and upper airways. Qual Assur 1993; 2: 213-31.
40. Shipley MT, Ennis M. Functional organization of olfactory system. J Neurobiol 1996; 30; 123-76.
41. Morrison EE, Costanzo RM. Morphology of olfactory epithelium in humans and other vertebrates. Microsc Res Technol 1992; 23: 49-61.
42. Harkema JR. Comparative aspects of nasal airway anatomy - Relevance to inhalation toxicology. Toxicol Pathol 1991; 19; 321-336.
43. Murray RC, Calof AL. Neuronal regeneration: Lessons from the olfactory system. Semin Cell Dev Biol 1999; 10: 421-31.
44. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: Fact or fiction? J Drug Target 1998; 5: 415-41.
45. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008; 60: 915-28.
46. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue, Adv Drug Deliv Rev 2003; 55: 329-47.
47. Vila A, Sanchez A, Perez C, Alonso MJ. Pla-peg nanospheres: new carriers for transmucosal delivery of proteins and plasmid DNA. Polym Adv Technol 2002; 13: 851-8.
48. Csaba N, Sanchez A, Fernandez-Megia E, Novoa-Carballal R, Alonso MJ. Chitosan nanoparticles for the delivery of plasmid DNA: preparation and characterisation. Eur J Pharm Sci 2004; 23: 54.
49. Fernandez UR, Romani D, Calvo P, Vila JJL, Alonso MJ. Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration. STP Pharma Sci 1999; 9: 429-36.
50. Tomasi M, Dertzbaugh MT, Hearn T, Hunter RL, Elson CO. Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization. Eur J Immunol 1997; 27(10); 2720-5.
51. Tafaghodi M, Jaafari MR, Sajadi TSA. Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN. Eur J Pharm Biopharm 2006; 64(2): 138-45.
52. Stanley AC, Buxton D, Innes EA, Huntley JF. Intranasal immunization with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cellmediated immunity in sheep. Vaccine 2004; 22(29-30): 3929-41.
53. Cui Z, Mumper RJ. Intranasal administration of plasmid DNA coated nanoparticles results in enhanced immune responses. J Pharm Pharmacol 2002; 54(9): 1195-203.
54. Misra A, Jogani V, Jinturkar K, Vyas T. Recent Patents Review on Intranasal Administration for CNS Drug Delivery. Recent Pat Drug Deliv Formul 2008; 2(1): 25-40(16).
55. Hsing-wen S, Hsiang-fa L, Hosheng T. Nanoparticles for protein drug delivery. US20097604795, 2009.
56. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999; 178: 55-65.
57. Soane RJ, Hinchcliffe M, Davis SS, Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001; 217: 183-91.
58. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001; 51: 81-96.
59. Dodane V, Khan MA, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999; 182: 21-32.
60. Sakane T, Akizuki M, Taki Y, Yamashita S, Sezaki H, Nadai T. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J Pharm Pharmacol 1995; 47: 379-81.
61. Sakane T, Akizuki M, Yamashita S, Nadai T, Hashida M, Sezaki H. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity the relation to the lipophilicity of the drug. Chem Pharm Bull 1991; 39: 2456-8.
62. Sakane T, Akizuki M, Yamashita S, Sezaki H, Nadai T. Direct drug transport from the rat nasal to the cerebrospinal fluid: the relation to the dissociation of the drug. J Pharm Pharmacol 1994; 46: 378-9.
63. Chou KJ, Donovan MD. Distribution of antihistamines into the CSF following intranasal delivery. Biopharm Drug Dispos 1997; 18: 335-46.
64. Dahlin M, Jansson B, Bjork E. Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci 2001; 14: 75-80.
65. Westin U, Piras E, Jansson B, Bergstrom U, Dahlin M, Brittebo E, et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 2005; 24: 565-73.
66. Merkus FW, Berg MP. Can nasal drug delivery bypass the bloodbrain barrier? Questioning the direct transport theory. Drugs 2007; 8: 133-44.
67. Illum L. Nasal drug delivery: possibilities, problems and solutions. J Control Release 2003; 87: 187-98.
68. Illum L. Nasal drug delivery: new, developments and strategies. Drug Discov Today 2002; 7: 1184-9.
69. Stoke DG, Reber KR, Waltzman LS, Erns C, Hamilton D, Gawareck D, et al. Analgesic efficacy and safety of morphinechitosan nasal solution in patients with moderate to severe pain following orthopedic surgery. Pain Med 2008; 9: 3-12.
70. Zhang QZ, Zha LS, Zhang Y, Jiang WM, Lu W, Shi ZQ, et al. The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. J Drug Targ 2006; 14: 281-90.
71. Betbeder D, Sperandio S, Latapie JP, Nadai J, Etienne A, Zajac JM, et al. Biovector (tm) nanoparticles improve antinociceptive efficacy of nasal morphine. Pharm Res 2000; 17: 743-8
72. Zhang Q, Jiang X, Jiang W, Lu W, Su L, Shi Z. Preparation of nimodipineloaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm 2004; 275: 85-96.
73. Vyas TK, Babbar AK, Sharma RK, Singh S, Mishra A. Intranasal Mucoadhesive Microemulsions of Clonazepam: Prelimary Studies on Brain targeting. J Pharm Sci 2006; 95(3): 570-80.
74. Gao X, Tao W, Lu W, Zhang Q, Zhang Y, Jiang X, et al. Lectinconjugated PEG-PLA nanoparticles: Preparation and brain delivery after intranasal administration. Biomaterials 2006; 27: 3482-90.
75. Vyas TK, Babbar AK, Sharma RK, Singh S, Mishra A. Intranasal Mucoadhesive Microemulsions of Zolmitriptan: Prelimary Studies on Brain targeting. J Drug Targ 2005; 13(5): 317-24.
76. Zhang QZ, Zha LS, Zhang Y, Jiang WM, Lu W, Shi ZQ, et al. The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. J Drug Targ 2006; 4(5): 281-90.
77. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008; 358: 285-29.
78. Jain AK, Khar RK, Ahmed FJ, Diwan PV. Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur J Pharm Biopharm 2008; 69: 426-35.
79. Michael JK, Abraham JD, Michael CV. Attenuation of kindles seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics 2009; 6(2): 359-71.
80. Vyas TK, Babbar AK, Sharma RK, Singh S, Mishra A. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS Pharm Sci Technol 2006; 6(4): E1-9.
81. Xiaoling G, Jun C, Weixing T, Jianhua Z, Qizhi Z, Hongzhuan C, et al. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int J Pharm 2007; 340(1-2): 207-15.
82. Dong WL, Shawna AS, Richard FL, Shyam SM. Thiolated chitosan nanoparticles enhance antiinflammatory effects of intranasally delivered theophylline. Respir Res 2006; 7(1): 112.
83. Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJ, et al. Compacted DNA nanoparticles administered to the nasa mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004; 15: 1255-69.
84. Ziady AG, Gedeon CR, Muhammed O, Stillwell V, Oette SM, Fink TL, et al. Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol Ther 2003; 8(6): 948-56.
85. Dyer M, Hinchcliffe M, Watts P, Casille J, Jabbal-Gill I, Nankervis R, et al. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res 2002; 19: 998-1008.
86. Illum L. Nanoparticle systems for nasal delivery of drugs: a real improvement over simple systems? J Pharm Sci 2006; 96: 473-83.
87. Chen F, Zhang ZR, Yuan F, Qin X, Wang M, Huang Y. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int J Pharm 2008; 349: 226-33.
88. Dalpiaz A., Gavini E, Colombo G, Russo P, Bortolotti F, Ferraro L, et al. Brain uptake of an anti-ischemic agent by nasal administration of microparticles. J Pharm Sci 2008; 97: 4889-903.
89. Huang Y, Donovan MD. Microsphere transport pathways in the rabbit nasal mucosa. Int J Pharm Adv 1996; 1: 298-309.
90. Des RA, Ragnarsson EGE, Gullberg E, Preat V, Schneider YJ, Artursson P. Transport of nanoparticles across an in vitro model of the human follicle associated epithelium. Eur J Pharm Sci 2005; 25: 455-65.
91. Kisan RJ, Manoj NG, Ishaque MS, Vilarsrao JK, Sambjahi SP. Nasal Drug Delivery System-Factors Affecting and Applications. Curr Drug Ther 2007; 2: 27-38.
92. Suman JD. Nasal drug delivery. Expert Opin Biol Ther 2003; 3(3): 519-23.
93. Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004; 26(3): 137-42.
94. Swift DL. Aerosol deposition and clearance in the human upper airways. Ann Biomed Eng 1981; 9: 593-604.
95. www.optinose.com
96. Agarwal A, Lariya N, Saraogi G, Dubey N, Agrawal H, Agrawal GP. Nanoparticles as novel carrier for brain delivery: a review. Curr Pharm Des 2009; 15(8): 917-25.
97. Crombez L, Morris MC, Deshayes S, Heitz F, Divita G. Peptidebased nanoparticle for ex vivo and in vivo drug delivery. Curr Pharm Des 2008; 14(34): 3656-65.
98. Venugopal J, Prabhakaran MP, Low S, Choon AT, Deepika G, Dev VR, et al. Continuous nanostructures for the controlled release of drugs. Curr Pharm Des 2009; 15(15): 1799-808.